東誠藥業(002675.SZ):東誠北方產品達肝素鈉注射液獲批生產上市
格隆匯10月31日丨東誠藥業(002675.SZ)公佈,近日,煙台東誠藥業集團股份有限公司收到全資子公司煙台東誠北方製藥有限公司(簡稱“東誠北方”)的通知,通知其收到國家藥品監督管理局下發的《藥品註冊證書》,公司產品達肝素鈉注射液獲批生產上市。
達肝素鈉注射液是一種低分子肝素製劑,主要成分為達肝素鈉,具有抗血栓形成和抗凝的作用,主要適應症:1、治療急性深靜脈血栓。2、預防急性腎功能衰竭或慢性腎功能不全者進行血液透析和血液過濾期間體外循環系統中的凝血。3、治療不穩定型冠狀動脈疾病,如:不穩定型心絞痛和非Q波型心肌梗死。4、預防與手術有關的血栓形成。
根據米內網數據統計顯示,2020年至2022年,達肝素鈉注射液(0.2ml:5000AXaIU)在中國公立醫院醫療機構銷售規模分別為4.19億元、4.84億元、5.60億元;達肝素鈉注射液(0.3ml:7500AXaIU)分別為0元、0.11億元、0.92億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.